| 1 |
2020 |
alpha2beta1 Integrin Is Required for Optimal NK Cell Proliferation during Viral Infection but Not for Acquisition of Effector Functions or NK Cell-Mediated Virus Control. |
ECTV |
| 2 |
2020 |
Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition. |
CMV, HCMV |
| 3 |
2020 |
Cutting Edge: STAT1-Mediated Epigenetic Control of Rsad2 Promotes Clonal Expansion of Antiviral NK Cells. |
--- |
| 4 |
2020 |
Cytomegalovirus protein m154 perturbs the adaptor protein-1 compartment mediating broad-spectrum immune evasion. |
AP-1, CMVs |
| 5 |
2020 |
Prophylactic and Therapeutic HBV Vaccination by an HBs-expressing Cytomegalovirus Vector Lacking an Interferon Antagonist in Mice. |
CMV, HCMV |
| 6 |
2019 |
A novel murine model of differentiation-mediated cytomegalovirus reactivation from latently infected bone marrow haematopoietic cells. |
BM, BMCs, DCs, GM-CSF, HCMV, HSCs, IL-4, LPS |
| 7 |
2019 |
Cytomegalovirus Evades TRAIL-Mediated Innate Lymphoid Cell 1 Defenses. |
CMV, cNK, ILCs, SG, TNF, TRAIL, TRAIL-DR |
| 8 |
2019 |
Immunization with a murine cytomegalovirus based vector encoding retrovirus envelope confers strong protection from Friend retrovirus challenge infection. |
CMV, Env, FV, SIV |
| 9 |
2019 |
Life-long control of cytomegalovirus (CMV) by T resident memory cells in the adipose tissue results in inflammation and hyperglycemia. |
CMV |
| 10 |
2019 |
The complex of MCMV proteins and MHC class I evades NK cell control and drives the evolution of virus-specific activating Ly49 receptors. |
--- |
| 11 |
2018 |
FcgammaRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines. |
CMV |
| 12 |
2018 |
IL-27 regulates the number, function and cytotoxic program of antiviral CD4 T cells and promotes cytomegalovirus persistence. |
CMV |
| 13 |
2017 |
Cutting Edge: NKG2D Signaling Enhances NK Cell Responses but Alone Is Insufficient To Drive Expansion during Mouse Cytomegalovirus Infection. |
--- |
| 14 |
2017 |
Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4+ and CD8+ T Cell Responses against Mouse Cytomegalovirus Infection. |
SLPs |
| 15 |
2017 |
Immune Protection by a Cytomegalovirus Vaccine Vector Expressing a Single Low-Avidity Epitope. |
--- |
| 16 |
2017 |
Mouse cytomegalovirus encoded immunoevasins and evolution of Ly49 receptors - Sidekicks or enemies? |
CMVs |
| 17 |
2017 |
Recent advances in CMV tropism, latency, and diagnosis during aging. |
CMV, HCMV |
| 18 |
2017 |
The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose. |
HCMV, LCMV |
| 19 |
2017 |
Two glycosaminoglycan-binding domains of the mouse cytomegalovirus-encoded chemokine MCK-2 are critical for oligomerization of the full-length protein. |
GAGs |
| 20 |
2017 |
UL36 Rescues Apoptosis Inhibition and In vivo Replication of a Chimeric MCMV Lacking the M36 Gene. |
CMV, HCMV |
| 21 |
2016 |
Bile Acids Act as Soluble Host Restriction Factors Limiting Cytomegalovirus Replication in Hepatocytes. |
CMV, TCDC |
| 22 |
2016 |
Conventional Dendritic Cells Confer Protection against Mouse Cytomegalovirus Infection via TLR9 and MyD88 Signaling. |
cDCs, CMV, DCs, MyD88, NK, pDCs, TLR9 |
| 23 |
2016 |
Cytomegalovirus-Specific CD4 T Cells Are Cytolytic and Mediate Vaccine Protection. |
APCs, CMV, CTL, MHC-II |
| 24 |
2016 |
Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus. |
HCMV, RPS14 |
| 25 |
2016 |
Inflammatory monocytes and NK cells play a crucial role in DNAM-1-dependent control of cytomegalovirus infection. |
DNAM, HCMV, PVR |
| 26 |
2016 |
Murine cytomegalovirus (CMV) infection via the intranasal route offers a robust model of immunity upon mucosal CMV infection. |
CMV |
| 27 |
2016 |
The Breadth of Synthetic Long Peptide Vaccine-Induced CD8+ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection. |
HCMV, SLP |
| 28 |
2016 |
Viral Persistence Induces Antibody Inflation without Altering Antibody Avidity. |
CMV, GC |
| 29 |
2015 |
Cutting edge: stage-specific requirement of IL-18 for antiviral NK cell expansion. |
--- |
| 30 |
2015 |
IL-33 receptor ST2 amplifies the expansion of NK cells and enhances host defense during mouse cytomegalovirus infection. |
--- |
| 31 |
2015 |
Mck2-dependent infection of alveolar macrophages promotes replication of MCMV in nodular inflammatory foci of the neonatal lung. |
CMV, MCK2, NIF |
| 32 |
2015 |
Type I Interferon Released by Myeloid Dendritic Cells Reversibly Impairs Cytomegalovirus Replication by Inhibiting Immediate Early Gene Expression. |
CMV, IE, IFN, mDC |
| 33 |
2014 |
"Activated" STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells. |
SOCS |
| 34 |
2014 |
CMV-induced pathology: pathway and gene-gene interaction analysis. |
CAF, HCMV, MEC, SGs, TME |
| 35 |
2014 |
Cutting edge: Salivary gland NK cells develop independently of Nfil3 in steady-state. |
SG |
| 36 |
2014 |
Cytomegalovirus generates long-lived antigen-specific NK cells with diminished bystander activation to heterologous infection. |
CMV, IFN, NK |
| 37 |
2014 |
Distinct requirements for activation of NKT and NK cells during viral infection. |
--- |
| 38 |
2014 |
Inhibition of the TRAIL death receptor by CMV reveals its importance in NK cell-mediated antiviral defense. |
CMV, DR, NK, ORF, TRAIL |
| 39 |
2014 |
M27 expressed by cytomegalovirus counteracts effective type I interferon induction of myeloid cells but not of plasmacytoid dendritic cells. |
CMV, RLH, TLR, TLR9 |
| 40 |
2014 |
Viral MHC class I-like molecule allows evasion of NK cell effector responses in vivo. |
Deltam157, MHC-I |
| 41 |
2013 |
Cytomegalovirus-induced salivary gland pathology: resistance to kinase inhibitors of the upregulated host cell EGFR/ERK pathway is associated with CMV-dependent stromal overexpression of IL-6 and fibronectin. |
HCMV, MEC, SG, SMGs |
| 42 |
2013 |
Priming of CD8+ T cells against cytomegalovirus-encoded antigens is dominated by cross-presentation. |
DCs |
| 43 |
2013 |
Superior induction and maintenance of protective CD8 T cells in mice infected with mouse cytomegalovirus vector expressing RAE-1gamma. |
CMVs, RAE-1gamma |
| 44 |
2013 |
Vascular dysfunction in young, mid-aged and aged mice with latent cytomegalovirus infections. |
HCMV |
| 45 |
2012 |
A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. |
CMV, PSA |
| 46 |
2012 |
Cytomegalovirus infection impairs immune responses and accentuates T-cell pool changes observed in mice with aging. |
CMV |
| 47 |
2012 |
Eri1 regulates microRNA homeostasis and mouse lymphocyte development and antiviral function. |
BM, NK |
| 48 |
2012 |
Immune senescence: relative contributions of age and cytomegalovirus infection. |
CMV, LCMV |
| 49 |
2012 |
Impact of local endothelial challenge with cytomegalovirus or glycoprotein B on vasodilation in intact pressurized arteries from nonpregnant and pregnant mice. |
CMV, gB, LP, NP |
| 50 |
2011 |
A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. |
CMV, EBOV, NP, ZEBOV |
| 51 |
2011 |
Dissecting the requirements for maintenance of the CMV-specific memory T-cell pool. |
CMV |
| 52 |
2011 |
Genetic labeling reveals altered turnover and stability of innate lymphocytes in latent mouse cytomegalovirus infection. |
--- |
| 53 |
2011 |
The mouse cytomegalovirus glycoprotein m155 inhibits CD40 expression and restricts CD4 T cell responses. |
CMV, ORF |
| 54 |
2010 |
Biphasic role of 4-1BB in the regulation of mouse cytomegalovirus-specific CD8(+) T cells. |
--- |
| 55 |
2010 |
Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines. |
HCMV |
| 56 |
2010 |
Differential effects on nitric oxide-mediated vasodilation in mesenteric and uterine arteries from cytomegalovirus-infected mice. |
CMV, NO, PGHS |
| 57 |
2010 |
The m74 gene product of murine cytomegalovirus (MCMV) is a functional homolog of human CMV gO and determines the entry pathway of MCMV. |
HCMV |
| 58 |
2009 |
Cytomegalovirus infection causes an increase of arterial blood pressure. |
ABP, Ang II, CMV, EC, ELISA, HCMV, HHV-8, QRT-PCR |
| 59 |
2008 |
Cytomegalovirus induces abnormal chondrogenesis and osteogenesis during embryonic mandibular development. |
CMV, MANs, NCM |
| 60 |
2008 |
Cytomegalovirus inhibition of embryonic mouse tooth development: a model of the human amelogenesis imperfecta phenocopy. |
CMV |
| 61 |
2008 |
Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. |
--- |
| 62 |
2008 |
Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. |
CNS, HCMV |
| 63 |
2006 |
Cytomegalovirus-induced embryopathology: mouse submandibular salivary gland epithelial-mesenchymal ontogeny as a model. |
CMV |
| 64 |
2004 |
Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation. |
APOE, CMV, p.i |
| 65 |
2003 |
Improved detection and quantification of mouse cytomegalovirus by real-time PCR. |
CMV |
| 66 |
1999 |
Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. |
--- |
| 67 |
1985 |
Studies of ocular murine cytomegalovirus infection. |
CMV, MEF, p.i, SG-MCMV |
| 68 |
1980 |
Adverse effects of cytomegalovirus vaccination in mice. |
CMV |
| 69 |
1979 |
Age-related neurocytotropism of mouse cytomegalovirus in explanted trigeminal ganglions. |
CMV, METC |
A Search Service for Abbreviation / Long Form
